Rare disease drugmaker X4 Pharma's Q4 revenue rises on XOLREMDI strength

X4 Pharmaceuticals

17/03/2026 11:29

Overview

Rare hematology drug developer's Q4 revenue reached $2.6 mln, driven by XOLREMDI sales and licensing

Company posted Q4 net loss of $23.9 mln, or $0.22 per share

Cash runway projected through 2028 after equity financings and expense reductions

Outlook

X4 says cash runway expected to fund operations through 2028

Result Drivers

CLINICAL TRIAL INVESTMENT - Investments in the 4WARD Phase 3 trial for chronic neutropenia contributed to operating expenses

LICENSING REVENUE - Q4 license and other revenue was attributable to the Norgine out-licensing agreement

Company press release: ID:nGNX7x7jZS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.22
Q4 Net Income
-$23.93 mln
Q4 Income from Operations
-$23.70 mln
Q4 Operating Expenses
$26.27 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $11.00, about 209% above its March 16 closing price of $3.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)